Procedures Jump 18% as da Vinci 5 Rollout Powers Fourth Quarter Beat (ISRG Q4 2025 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Intuitive Surgical capped a stellar 2025 with rapid adoption of its next-generation da Vinci 5 platform and robust procedure volume expansion. While the company faces margin pressures from supply chain tariffs and geographic headwinds in Asia, broad-based clinical demand for minimally invasive surgery continues to power double-digit revenue growth and consistent installed base expansion.
Strong Procedure Growth Fuels Q4 Revenue Beat
Intuitive Surgical delivered an impressive 19% revenue increase to $2.87 billion in the fourth quarter, driven by robust utilization across its product ecosystem. Overall procedure volume climbed 18% year-over-year, anchored by a 15% increase in U.S. da Vinci procedures and surging 44% growth in the Ion endoluminal platform. The company's recurring revenue remains its financial bedrock, jumping 20% to $2.3 billion and representing 81% of total sales for the quarter.
da Vinci 5 Drives Robust System Placements
The rollout of the next-generation da Vinci 5 system accelerated, accounting for 303 of the 532 total da Vinci systems placed in the fourth quarter. CEO Dave Rosa highlighted that "demand for da Vinci 5 strengthened throughout the year with customers responding to broader availability." This upgrade cycle drove 146 trade-in transactions, a significant increase from 62 a year ago, allowing Intuitive to refurbish older Xi systems to target the price-sensitive ambulatory surgery center market.
Broadening Clinical Indications and Market Access
The company successfully expanded its clinical footprint, securing FDA clearance for several cardiac procedures on da Vinci 5 using non-Force Feedback instruments. Additionally, the single-port platform gained regulatory momentum, receiving clearances for nipple-sparing mastectomy and various general surgery procedures. This clinical diversification helped international da Vinci procedures grow 21%, despite intensifying domestic competition in China where provincial tenders heavily favored local robotic suppliers.
2026 Outlook Navigates Continued Margin Pressures
Looking to 2026, management forecasts full-year da Vinci procedure growth between 13% and 15%. However, profitability faces external headwinds, with pro forma gross profit margin projected between 67% and 68%. CFO Jamie Samath noted that this guidance absorbs an expected "impact from tariffs of 1.2% of net revenue," alongside the dilutive effect of a higher mix of lower-margin da Vinci 5 systems that have not yet achieved their target manufacturing cost curves.